When Isis Pharmaceuticals Inc.'s Kynamro (mipomersen) was approved in January 2013 by the FDA for homozygous familial hypercholesterolemia (HoFH), the big question was whether the weekly injectable apolipoprotein B synthesis inhibitor could stand up against the daily pill from Aegerion Pharmaceuticals Inc.'s Juxtapid (lomitapide), a microsomal triglyceride transfer protein blocker for the same indication.